127 related articles for article (PubMed ID: 11841383)
1. Cutaneous large B-cell lymphoma of the leg masquerading as a chronic venous ulcer.
Garbea A; Dippel E; Hildenbrand R; Bleyl U; Schadendorf D; Goerdt S
Br J Dermatol; 2002 Jan; 146(1):144-7. PubMed ID: 11841383
[TBL] [Abstract][Full Text] [Related]
2. Complete remission of a primary cutaneous B-cell lymphoma of the lower leg by first-line monotherapy with the CD20-antibody rituximab.
Bonnekoh B; Schulz M; Franke I; Gollnick H
J Cancer Res Clin Oncol; 2002 Mar; 128(3):161-6. PubMed ID: 11935303
[TBL] [Abstract][Full Text] [Related]
3. Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas--an applicational observation.
Gellrich S; Muche JM; Wilks A; Jasch KC; Voit C; Fischer T; Audring H; Sterry W
Br J Dermatol; 2005 Jul; 153(1):167-73. PubMed ID: 16029344
[TBL] [Abstract][Full Text] [Related]
4. Primary cutaneous large B-cell lymphoma of the legs: a distinct clinical pathologic entity treated with CD20 monoclonal antibody (rituximab).
Aboulafia DM
Am J Clin Oncol; 2001 Jun; 24(3):237-40. PubMed ID: 11404492
[TBL] [Abstract][Full Text] [Related]
5. Rituximab in cutaneous B-cell lymphoma: a report of two cases.
Sabroe RA; Child FJ; Woolford AJ; Spittle MF; Russell-Jones R
Br J Dermatol; 2000 Jul; 143(1):157-61. PubMed ID: 10886152
[TBL] [Abstract][Full Text] [Related]
6. [Relapse of diffuse large B cell lymphoma to CD20-negative multiple cutaneous tumors immediately after anti-CD20 monoclonal antibody (rituximab) therapy].
Iguchi T; Miyazawa K; Okabe S; Kawakubo K; Shimamoto T; Kuriyama Y; Ito Y; Kimura Y; Ohyashiki K; Serizawa H; Iwaya K; Mukai K
Rinsho Ketsueki; 2004 Oct; 45(10):1129-34. PubMed ID: 15553050
[TBL] [Abstract][Full Text] [Related]
7. [Anti-CD20 antibodies in primary cutaneous B-cell lymphoma. Initial results in dermatologic patients].
Gellrich S; Muche JM; Pelzer K; Audring H; Sterry W
Hautarzt; 2001 Mar; 52(3):205-10. PubMed ID: 11284065
[TBL] [Abstract][Full Text] [Related]
8. [Cutaneous B-cell lymphoma treatment with rituximab: two cases].
Viguier M; Bachelez H; Brice P; Rivet J; Dubertret L
Ann Dermatol Venereol; 2002 Oct; 129(10 Pt 1):1152-5. PubMed ID: 12442128
[TBL] [Abstract][Full Text] [Related]
9. Rituximab monotherapy for primary cutaneous B-cell lymphoma: response and follow-up in 16 patients.
Valencak J; Weihsengruber F; Rappersberger K; Trautinger F; Chott A; Streubel B; Muellauer L; Der-Petrossian M; Jonak C; Binder M; Raderer M
Ann Oncol; 2009 Feb; 20(2):326-30. PubMed ID: 18836086
[TBL] [Abstract][Full Text] [Related]
10. Treatment of radiation-relapsing primary cutaneous B-cell lymphoma with an anti-CD20 monoclonal antibody.
Lacouture ME; Baron JM; Jani AB; Laumann AE; Soltani K
Clin Exp Dermatol; 2005 Jan; 30(1):46-8. PubMed ID: 15663503
[TBL] [Abstract][Full Text] [Related]
11. Intralesional therapy with anti-CD20 monoclonal antibody rituximab: local and systemic efficacy in primary cutaneous B-cell lymphoma.
Roguedas AM; Watier H; Paintaud G; de Muret A; Vaillant L; Machet L
Br J Dermatol; 2005 Mar; 152(3):541-4. PubMed ID: 15787825
[TBL] [Abstract][Full Text] [Related]
12. Intralesional therapy with anti-CD20 monoclonal antibody rituximab in primary cutaneous B-cell lymphoma.
Heinzerling L; Dummer R; Kempf W; Schmid MH; Burg G
Arch Dermatol; 2000 Mar; 136(3):374-8. PubMed ID: 10724200
[TBL] [Abstract][Full Text] [Related]
13. Treatment of primary cutaneous follicular centre lymphoma with rituximab: a report of two cases.
Kennedy GA; Blum R; McCormack C; Prince HM
Australas J Dermatol; 2004 Feb; 45(1):34-7. PubMed ID: 14961906
[TBL] [Abstract][Full Text] [Related]
14. Cutaneous B-cell lymphoma with loss of CD20 immunoreactivity after rituximab therapy.
Clarke LE; Bayerl MG; Ehmann WC; Helm KF
J Cutan Pathol; 2003 Aug; 30(7):459-62. PubMed ID: 12859745
[TBL] [Abstract][Full Text] [Related]
15. Large B-cell lymphoma of the leg: clinical and pathologic characteristics in a North American series.
Brogan BL; Zic JA; Kinney MC; Hu JY; Hamilton KS; Greer JP
J Am Acad Dermatol; 2003 Aug; 49(2):223-8. PubMed ID: 12894069
[TBL] [Abstract][Full Text] [Related]
16. Intralesional rituximab for cutaneous B-cell lymphoma.
Paul T; Radny P; Kröber SM; Paul A; Blaheta HJ; Garbe C
Br J Dermatol; 2001 Jun; 144(6):1239-43. PubMed ID: 11422050
[TBL] [Abstract][Full Text] [Related]
17. Cutaneous B-cell lymphoma responds to rituximab: a report of five cases and a review of the literature.
Gitelson E; Al-Saleem T; Millenson M; Lessin S; Smith MR
Leuk Lymphoma; 2006 Sep; 47(9):1902-7. PubMed ID: 17065004
[TBL] [Abstract][Full Text] [Related]
18. Rituximab in the treatment of primary cutaneous B-cell lymphoma: a review.
Fernández-Guarino M; Ortiz-Romero PL; Fernández-Misa R; Montalbán C
Actas Dermosifiliogr; 2014 Jun; 105(5):438-45. PubMed ID: 23540593
[TBL] [Abstract][Full Text] [Related]
19. Dramatical improvement of chemoresistant bone lymphoma with rituximab.
Achemlal L; Mikdame M; Nouijai A; Bezza A; El Maghraoui A
Clin Rheumatol; 2006 May; 25(3):394-5. PubMed ID: 16247586
[TBL] [Abstract][Full Text] [Related]
20. Systemic therapy of primary cutaneous B-cell lymphoma, marginal zone type, with rituximab, a chimeric anti-CD20 monoclonal antibody.
Soda R; Costanzo A; Cantonetti M; Orlandi A; Bianchi L; Chimenti S
Acta Derm Venereol; 2001; 81(3):207-8. PubMed ID: 11558880
[No Abstract] [Full Text] [Related]
[Next] [New Search]